Table 3 The change in median values for each variable during the one-year treatment with metformin
Baseline (N = 88) | 3 months (N = 85) | 6 months (N = 87) | 12 months (N = 61) | Time Estimate (months) | p-value | |
|---|---|---|---|---|---|---|
BMI (kg/m2) | 23.2 (20.6–29.8) | 22.7* (20.7–29.3) | 22.7* (20.7–29.0) | 22.6* (20.5–29.0) | − 0.048 | 0.123 |
Testosterone (ng/ml) | 0.61 (0.41–0.81) | 0.48* (0.33–0.68) | 0.40* (0.26–0.60) | 0.36* (0.28–0.52) | − 0.019 | < 0.001** |
SHBG (nmol/l) | 31.1 (19.0–45.0) | 30.5 (20.0–46.6) | 32.4 (18.8–46.0) | 17.3* (17.7–36.7) | − 0.323 | 0.014** |
FAI (%) | 6.84 (4.07–11.86) | 5.05* (3.53–8.34) | 4.27* (2.52–8.34) | 5.06* (3.10–7.53) | − 0.178 | < 0.001** |
Fasting glucose (mg/dL) | 82 (78–87) | 82 (77–85) | 81* (78–85) | 84 (79–87) | 0.046 | 0.437 |
Fasting insulin (mIU/L) | 4.27 (2.00–12.93) | 3.70 (2.00–11.25) | 4.97 (2.00–9.79) | 4.28 (2.00–9.04) | − 0.137 | 0.083 |
HOMA-IR | 0.84 (0.41–2.68) | 0.76* (0.39–2.28) | 0.95 (0.40–2.07) | 0.75 (0.41–1.84) | −0.029 | 0.103 |
GOT(U/L) | 19 (17–23) | 18 (15–23) | 17* (15–21) | 16* (13–20) | − 0.498 | 0.002** |
GPT (U/L) | 17 (12–24) | 17 (12–29) | 15* (10–23) | 12* (9–18) | −0.739 | 0.012** |
SBP (mmHg) | 112 (105–124) | 112 (104–122) | 112 (105–122) | 109* (101–118) | −0.251 | 0.010** |
DBP (mmHg) | 72 (66–78) | 72 (65–79) | 71* (65–79) | 70* (63–77) | −0.274 | < 0.001** |
hsCRP (mg/dL) | 0.088 (0.038–0.287) | 0.099 (0.015–0.262) | 0.093 (0.028–0.283) | 0.062* (0.026–0.252) | −0.006 | 0.267 |
mtDNA-CN | 55.38 (26.14–100.27) | 34.78 (19.27–78.08) | 33.42* (20.45–55.78) | 24.11* (16.92–66.75) | −4.509 | 0.003** |
8-OHdG | 34.62 (27.70–45.44) | 31.95* (23.07–42.12) | 29.96* (21.21–39.09) | 18.57* (12.13–31.15) | −1.299 | < 0.001** |